Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inovio Pharmaceuticals

1.85
+0.07003.93%
Post-market: 1.84-0.0100-0.54%17:29 EDT
Volume:504.29K
Turnover:923.66K
Market Cap:67.83M
PE:-0.47
High:1.86
Open:1.80
Low:1.78
Close:1.78
Loading ...

Inovio Pharmaceuticals Inc - Dmab Levels Remain Stable for 72 Weeks in All Participants

THOMSON REUTERS
·
14 Mar

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

PR Newswire
·
14 Mar

Inovio Pharmaceuticals Inc. Stock Falls 5.9%, Underperforms Competitors

Dow Jones
·
14 Mar

Inovio Pharmaceuticals Inc. Stock Rises Wednesday, Still Underperforms Market

Dow Jones
·
06 Mar

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
05 Mar

Inovio Pharmaceuticals Inc. Stock Sheds 7.1%, Underperforms Competitors

Dow Jones
·
04 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
01 Mar

Inovio Pharmaceuticals Inc expected to post a loss of 84 cents a share - Earnings Preview

Reuters
·
01 Mar

Inovio Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
26 Feb

Inovio Pharmaceuticals Inc. Stock Slips 9.8%, Underperforms Competitors

Dow Jones
·
25 Feb

Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
19 Feb

Inovio Pharmaceuticals Inc. Stock Advances 12.1%, Outperforms Competitors

Dow Jones
·
13 Feb

Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher

Zacks
·
12 Feb

BRIEF-Inovio Pharmaceuticals' Phase 1/2 Study Results Published In Nature Communications

Reuters
·
12 Feb

Inovio announces peer-reviewed data from phase 1/2 clinical trial with INO-307

TIPRANKS
·
12 Feb

Inovio Pharmaceuticals Inc - Phase 1/2 Study Results of Ino-3107 Published in Nature Communications

THOMSON REUTERS
·
12 Feb

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

PR Newswire
·
12 Feb

Inovio Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
11 Feb

BRIEF-Immune Response Data For INO-3107 To Be Presented As A Poster At American Association For Cancer Research Immuno-Oncology Conference

Reuters
·
10 Feb